ReNerve Limited (ASX:RNV)

Australia · Delayed Price · Currency is AUD

0.0740

+0.0030 (4.23%)

At close: Sep 18, 2026

Market Cap	12.23M -26.1%
Revenue (ttm)	510.36K +87.8%
Net Income	-5.57M
EPS	-0.04
Shares Out	172.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	175,053
Open	0.0710
Previous Close	0.0710
Day's Range	0.0710 - 0.0740
52-Week Range	0.0680 - 0.2200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 11, 2026

About ReNerve

ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures in New Zealand and the United States. It develops Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and Nerve Graft, an off-the-shelf nerve grafts for the repair of damaged nerves under the NervAlign brand. The company also offers Empliq Dermal, an acellular dermal matrix (ADM) sourced from donated human skin and designed to replace lost or damaged der... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2016

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol RNV

Full Company Profile

Financial Performance

In fiscal year 2026, ReNerve's revenue was 510,357, an increase of 87.83% compared to the previous year's 271,707. Losses were -5.57 million, 49.2% more than in 2025.

Financial Statements